Ian Chau

2002–2025 年に発表

162
論文数
41,474
被引用数
81
h 指数
155
i10 指数

被引用数

Ian Chau の年別被引用数1979 年: 被引用 1 件1991 年: 被引用 1 件1994 年: 被引用 2 件1996 年: 被引用 1 件1998 年: 被引用 1 件1999 年: 被引用 2 件2001 年: 被引用 1 件2002 年: 被引用 2 件2003 年: 被引用 3 件2004 年: 被引用 16 件2005 年: 被引用 94 件2006 年: 被引用 119 件2007 年: 被引用 143 件2008 年: 被引用 131 件2009 年: 被引用 141 件2010 年: 被引用 148 件2011 年: 被引用 134 件2012 年: 被引用 112 件2013 年: 被引用 121 件2014 年: 被引用 157 件2015 年: 被引用 157 件2016 年: 被引用 245 件2017 年: 被引用 329 件2018 年: 被引用 333 件2019 年: 被引用 1,458 件2020 年: 被引用 1,914 件2021 年: 被引用 1,813 件2022 年: 被引用 1,639 件2023 年: 被引用 1,367 件2024 年: 被引用 2,109 件2025 年: 被引用 965 件2026 年: 被引用 18 件1980〜1990 年は被引用が無いため表示していません1992〜1993 年は被引用が無いため表示していません1995 年は被引用が無いため表示していません1997 年は被引用が無いため表示していません2000 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,288 件、この内訳の 21.7%中国: 引用元論文 2,720 件、この内訳の 13.8%イタリア: 引用元論文 1,342 件、この内訳の 6.8%イギリス: 引用元論文 1,167 件、この内訳の 5.9%ドイツ: 引用元論文 1,061 件、この内訳の 5.4%日本: 引用元論文 971 件、この内訳の 4.9%フランス: 引用元論文 901 件、この内訳の 4.5%スペイン: 引用元論文 733 件、この内訳の 3.7%オランダ: 引用元論文 628 件、この内訳の 3.2%カナダ: 引用元論文 549 件、この内訳の 2.8%韓国: 引用元論文 489 件、この内訳の 2.5%スイス: 引用元論文 436 件、この内訳の 2.2%
0%21.7%その他 22.6%

分野

  • Medicine79.4%
  • Biochemistry, Genetics and Molecular Biology14.1%
  • Immunology and Microbiology2%
  • Engineering1.7%
  • Mathematics0.4%
  • Neuroscience0.4%
  • その他2%

トピック

  • Cancer Immunotherapy and Biomarkers9.1%
  • Colorectal Cancer Treatments and Studies5.1%
  • Hepatocellular Carcinoma Treatment and Prognosis3.7%
  • Cancer Genomics and Diagnostics3.4%
  • Pancreatic and Hepatic Oncology Research3.2%
  • Gastric Cancer Management and Outcomes3.1%
  • その他72.4%

共著者

全論文

検索で開く
  1. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pauline Funchain, Kathryn Bollin - Journal of Clinical Oncology 2021 被引用: 1,964

  2. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mitch Dowsett, Johann S. de Bono, Paul Workman, Anguraj Sadanandam, Matteo Fassan, Owen J. Sansom, Suzanne A. Eccles, Naureen Starling, Chiara Braconi, Andrea Sottoriva, Simon P. Robinson, David Cunningham, Nicola Valeri - Science 2018 被引用: 2,131

  3. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 被引用: 3,697

  4. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 被引用: 1,181

  5. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Doki, Yuichiro, Ajani, Jaffer A., Kato, Ken, Xu, Jianming, Wyrwicz, Lucjan, Motoyama, Satoru, Ogata, Takashi, Kawakami, Hisato, Hsu, Chih Hung, Adenis, Antoine, Di Bartolomeo, Maria, Braghiroli, Maria I., Holtved, Eva, Ostoich, Sandra A., Kim, Hye R., Ueno, Masaki, Mansoor, Wasat, Yang, Wen Chi, Liu, Tianshu, Bridgewater, John, Makino, Tomoki, Xynos, Ioannis, Liu, Xuan, Lei, Ming, Kondo, Kaoru, Patel, Apurva, Gricar, Joseph, Chau, Ian, Kitagawa, Yuko - 2022 被引用: 532

  6. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , , , , , - Annals of Oncology 2018 被引用: 1,070

  7. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kathryn Bollin, Monalisa Ghosh - Journal of Clinical Oncology 2021 被引用: 376

  8. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    著者: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 1,734

  9. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

    著者: , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2021 被引用: 443

  10. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

    著者: , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 242

  11. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2013 被引用: 2,200

  12. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 1,254

  13. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

    著者: , , , , , , , , , , , - New England Journal of Medicine 2004 被引用: 5,049

  14. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

    著者: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 458

  15. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 被引用: 631

  16. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 919

  17. Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sebastian Guettler, Katharina von Loga, Sheela Rao, David Watkins, Naureen Starling, Ian Chau, Anguraj Sadanandam, David Cunningham, Marco Gerlinger - Cancer Cell 2019 被引用: 262

  18. MRI-Diagnosed Tumor Deposits and EMVI Status Have Superior Prognostic Accuracy to Current Clinical TNM Staging in Rectal Cancer

    著者: , , , , , , , , , , - Annals of Surgery 2020 被引用: 196

  19. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 845

  20. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Per Pfeiffer, Naotoshi Sugimoto, Judit Kocsis, Andràs Csilla, G. Bodoky, Georgina Garnica Jaliffe, Светлана Проценко, Ayman Madi, Elżbieta Wójcik, Baruch Brenner, Gunnar Folprecht, Tomasz Sarosiek, Katriina Peltola, Peter Bono, Hubert Ayala, Giuseppe Aprile, Cardellino Giovanni Gerardo, Fidel David Huitzil Melendez, Alfredo Falcone, Francesco Di Costanzo, Moustapha Tehfe, Laurent Mineur, Pilar Alfonso, Radka Obermannová, Hélène Senellart, Russell Petty, Leslie Samuel, Péter Ács, Maen Hussein, M. Nechaeva, Frans Erdkamp, Elizabeth Won, Johanna C. Bendell, Javier Gállego, Sylvie Lorenzen, Bohuslav Melichar, Miguel Angel Escudero, Denis Pezet, Jean–Marc Phelip, Diego Kaen, James A. Reeves, Federico Longo Muñoz, Srinivasan Madhusudan, Carlo Barone, Luis Fein, Ángel Gómez Villanueva, Mohamed Hebbar, Jana Prausová, L. Visa Turmo, J. Vidal Barrull, Mette Yilmaz, Alex Beny, Hanneke W.M. van Laarhoven, Brian DiCarlo, Taito Esaki, Kazumasa Fujitani, Karen Geboes, Ravit Geva, Shigenori Kadowaki, Stephen Leong, Nozomu Machida, Moses S. Raj, Francisco Javier Ramírez Godinez, Ágnes Ruzsa, Hugo Ford, William Lawler, Nicolas Robert Maisey, Jiřı́ Petera, Einat Shacham‐Shmueli, Isabelle Sinapi ほか 44 名 - The Lancet Oncology 2019 被引用: 284

  21. BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 被引用: 331

  22. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

    著者: , , , , , , , , , , , , , , , , , , , - Gastric Cancer 2021 被引用: 166

  23. Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

    著者: , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2017 被引用: 405

  24. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2019 被引用: 275